[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-operative-hematoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-operative-hematoma":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100560277",false,"NCT06575049","Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery","Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients","Inclusion Criteria:\n\n* Systemic performance status 0-2 according to ECOG criteria\n* Patients with adequate renal function: serum Cr 1.4 mg\u002FdL or less\n* Patients with adequate liver function Bilirubin, AST\u002FALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal\n* Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)\n* Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)\n* Patients who voluntarily decided to participate in this study and signed a written informed consent form\n\nExclusion Criteria:\n\n* Patients undergoing immediate reconstruction operation\n* Patients with drug allergies to painkillers and anti-inflammatory drugs\n* Patients with a physical condition that would interfere with understanding and submitting the consent form","FEMALE","20 Years","70 Years",{"count":19,"type":20},60,"ESTIMATED","3 Months","OBSERVATIONAL","The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.",[25,26,27,28],"Breast Cancer","Post-Operative Hematoma","Seroma as Procedural Complication","Post-Op Complication","NOT_YET_RECRUITING","2024-09-02",{"date":32,"type":33},"2024-09-19","ACTUAL",{"date":35,"type":20},"2025-05-01",{"date":37,"type":20},"2026-02-20",{"name":39,"class":40},"Seoul National University Hospital","OTHER",""]